Sleep and neurological autoimmune diseases.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
03
03
2019
accepted:
02
07
2019
revised:
17
06
2019
pubmed:
16
7
2019
medline:
17
12
2020
entrez:
15
7
2019
Statut:
ppublish
Résumé
Neurological autoimmune diseases are characterized by an inappropriate immune response that by mistake targets the nervous system. As a result, patients experiment a number of neurological manifestations that may include insomnia, excessive daytime sleepiness, cataplexy, central hypoventilation, and REM sleep behavior disorder. Polysomnographic evaluation may reveal disorganized sleep architecture involving both NREM and REM sleep, and REM sleep intrusions into wakefulness. The study of sleep disorders in the setting of autoimmune diseases (e.g., narcolepsy, anti-IgLON5 disease, paraneoplastic neurological syndromes) shows that an abnormal immune-mediated (humoral or cellular) response target the neuronal structures (e.g., brainstem, hypothalamus) and neurotransmitters systems (e.g., hypocretin) that regulate sleep resulting in sleep impairment. It is a window to examine the link between the autoimmune system and the sleep regulation at the molecular, cellular, and anatomic level.
Identifiants
pubmed: 31302665
doi: 10.1038/s41386-019-0463-z
pii: 10.1038/s41386-019-0463-z
pmc: PMC6879573
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-140Références
American Academy of Sleep Medicine. International classification of sleep disorders, 3rd edn. Darien, IL: American Academy of Sleep Medicine, 2014.
Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499–511.
doi: 10.1016/S0140-6736(07)60237-2
Plazzi G, Pizza F, Palaia V, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain. 2011;134:3477–89.
doi: 10.1093/brain/awr244
pubmed: 3235554
pmcid: 3235554
de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322–7.
doi: 10.1073/pnas.95.1.322
Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996–10015.
doi: 10.1523/JNEUROSCI.18-23-09996.1998
pubmed: 9822755
pmcid: 9822755
Nevarez N, de Lecea L. Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation. F1000Res. 2018;7:F1000 Faculty Rev–1421.
doi: 10.12688/f1000research.15097.1
Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991–7.
doi: 10.1038/79690
pubmed: 10973318
pmcid: 10973318
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39–40.
doi: 10.1016/S0140-6736(99)05582-8
pubmed: 10615891
pmcid: 10615891
Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol. 2008;7:649–62.
doi: 10.1016/S1474-4422(08)70140-6
pubmed: 18565458
pmcid: 18565458
Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469–74.
doi: 10.1016/S0896-6273(00)00058-1
pubmed: 11055430
Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20:83–93.
doi: 10.1038/s41583-018-0097-x
pubmed: 6492289
pmcid: 6492289
Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32:979–83.
doi: 10.1093/sleep/32.8.979
pubmed: 19725248
pmcid: 2717204
Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70:410–17.
doi: 10.1002/ana.22587
pubmed: 21866560
pmcid: 21866560
Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13:600–13.
doi: 10.1016/S1474-4422(14)70075-4
pubmed: 24849861
pmcid: 24849861
Latorre D, Kallweit U, Armentani E, et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018;562:63–68.
doi: 10.1038/s41586-018-0540-1
pubmed: 30232458
pmcid: 30232458
Lecendreux M, Churlaud G, Pitoiset F, et al. Narcolepsy type 1 is associated with a systemic increase and activation of regulatory t cells and with a systemic activation of global T cells. PLoS ONE. 2017;12:e0169836.
doi: 10.1371/journal.pone.0169836
pubmed: 28107375
pmcid: 28107375
Pedersen NW, Holm A, Kristensen NP, et al. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat Commun. 2019;10:837.
doi: 10.1038/s41467-019-08774-1
pubmed: 30783092
pmcid: 30783092
Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39–57.
doi: 10.2147/NSS.S103467
pubmed: 28424564
pmcid: 28424564
Barateau L, Lopez R, Dauvilliers Y. Management of Narcolepsy. Curr Treat Options Neurol. 2016;18:43.
doi: 10.1007/s11940-016-0429-y
pubmed: 27549768
pmcid: 27549768
Lammers GJ. Drugs used in narcolepsy and other hypersomnias. Sleep Med Clin. 2018;13:183–89.
doi: 10.1016/j.jsmc.2018.02.009
pubmed: 29759269
Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575–86.
doi: 10.1016/S1474-4422(14)70051-1
pubmed: 24703753
pmcid: 4104022
Högl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385:1590.
doi: 10.1016/S0140-6736(15)60445-7
pubmed: 25933285
Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136.
doi: 10.1212/NXI.0000000000000136
pubmed: 26236762
pmcid: 4516399
Montojo MT, Piren V, Benkhadra F, et al. Mimicking progressive supranuclear palsy and causing Tako-Tsubo syndrome: a case report on IgLON5 encephalopathy [abstract]. Mov Disord. 2015;30:710.
Brüggemann N, Wandinger KP, Gaig C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31:762–64.
doi: 10.1002/mds.26608
pubmed: 27030137
Schröder JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm. 2016;4:e302.
doi: 10.1212/NXI.0000000000000302
pubmed: 27900347
pmcid: 5120591
Haitao R, Yingmai Y, Yan H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9–10.
doi: 10.1016/j.jneuroim.2016.09.012
pubmed: 27806876
Zhang W, Niu N, Cui R. Serial 18F-FDG PET/CT findings in a patient with IgLON5 encephalopathy. Clin Nucl Med. 2016;41:787–88.
doi: 10.1097/RLU.0000000000001339
pubmed: 27556794
Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132:531–43.
doi: 10.1007/s00401-016-1591-8
pubmed: 27358064
pmcid: 5023728
Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43.
doi: 10.1212/WNL.0000000000003887
pubmed: 5409845
pmcid: 5409845
Cagnin A, Mariotto S, Fiorini M, et al. Microglial and neuronal TDP-43 pathology in anti-IgLON5-related taupathy. J Clin Alzheimer’s Dis. 2017;59:13–20.
doi: 10.3233/JAD-170189
Honorat JA, Lomorowski L, Josephs KA, et al. IgLON5 antibody. Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4:e385.
doi: 10.1212/NXI.0000000000000385
pubmed: 5515599
pmcid: 5515599
Bahtz R, Teegen B, Borowski K, et al. Autonatibodies against IgLON5: two new cases. J Neuroimmunol. 2014;275:8.
doi: 10.1016/j.jneuroim.2014.08.027
Bonello M, Jacob A, Ellul MA, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e383.
doi: 10.1212/NXI.0000000000000383
pubmed: 5567142
pmcid: 5567142
Wenninger S. Expanding the cinical spectrum of IgLON5-syndrome. J Neuromuscul Dis. 2017;4:337–39.
doi: 10.3233/JND-170259
Montagna M, Amir R, De Volder I, Lammens M, Huyskens J, Willekens B. IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes. Front Neurol 2018;9:329.
doi: 10.3389/fneur.2018.00329
pubmed: 5966542
pmcid: 5966542
Tao QQ, Wei Q, Song SJ, Yin XZ. Motor neuron disease-like phenotype associated with anti-IgLON5 disease. CNS Neurosci Ther. 2018;24:1305–08.
doi: 10.1111/cns.13038
pubmed: 6490080
pmcid: 6490080
Ramanan VK, Crum BA, McKeon A. Subacute encephalitis with recovery in IgLON5 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2018;5:e485.
doi: 10.1212/NXI.0000000000000485
pubmed: 6117189
pmcid: 6117189
Moreno-Estébanez A, Garcia-Ormaechea M, Tijero B, et al. Anti-IgLON5 disease responsive to immunotherapy: a case report with an abnormal MRI. Mov Disord Clin Pr. 2018;5:653–56.
doi: 10.1002/mdc3.12679
Morales-Briceño H, Cruse B, Fois AF, et al. IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease. Neurology. 2018;90:1113–15.
doi: 10.1212/WNL.0000000000005679
pubmed: 29769372
pmcid: 29769372
Schöberl F, Levin J, Remi J, et al. IgLON5: a case with predominant cerebellar tau deposits and leptomeningeal inflammation. Neurology. 2018;91:180–82.
doi: 10.1212/WNL.0000000000005859
pubmed: 29970401
pmcid: 29970401
Vetter E, Olmes DG, Linker R, Seifert F. Teaching video neuroImages: facial myokymia and myorhythmia in anti-IgLON5 disease: The bitten lip. Neurology. 2018;91:e1659.
doi: 10.1212/WNL.0000000000006388
pubmed: 30348862
pmcid: 30348862
Logmin K, Moldovan AS, Elben S, Schnitzler A, Groiss SJ Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy. J Neurol 2019. https://doi.org/10.1007/s00415-019-09221-3 .
Gaig C, Compta Y Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Curr Opin Neurol 2019. https://doi.org/10.1097/WCO.0000000000000677 .
Hasselbacher K, Steffen A, Wandinger KP, Brüggemann N. IgLON5 antibodies are infrequent in patients with isolated sleep apnea. Eur J Neurol. 2018;25:e46–e47. https://doi.org/10.1111/ene.13566 .
doi: 10.1111/ene.13566
pubmed: 29575362
pmcid: 29575362
Mangesius S, Sprenger F, Höftberger R, Seppi K, Reindl M, Poewe W. IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. Park Relat Disord. 2017;38:102–03.
doi: 10.1016/j.parkreldis.2017.03.002
Heidbreder A, Philipp K. Anti-IgLON 5 Disease. Curr Treat Options Neurol. 2018;20:29
doi: 10.1007/s11940-018-0515-4
pubmed: 29936617
pmcid: 29936617
Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflamm. 2016;13:226. https://doi.org/10.1186/s12974-016-0689-1 .
doi: 10.1186/s12974-016-0689-1
Dauvilliers Y, Mayer G, Lecendreux M, et al. Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. Neurology. 2002;59:1739–45.
doi: 10.1212/01.WNL.0000036605.89977.D0
pubmed: 12473762
pmcid: 12473762
Caminero A, Bartolomé M. Sleep disturbances in multiple sclerosis. J Neurol Sci. 2011;309:86–91.
doi: 10.1016/j.jns.2011.07.015
pubmed: 21813138
Braley TJ. Overview: a framework for the discussion of sleep in multiple sclerosis. Curr Sleep Med Rep. 2017;3:263–71.
doi: 10.1007/s40675-017-0092-1
pubmed: 30034994
pmcid: 6051415
Foschi M, Rizzo G, Liguori R, et al. Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. Sleep Med. 2019;56: 90–97.
Sakkas GK, Giannaki CD, Karatzaferi C, Manconi M. Sleep abnormalities in multiple sclerosis. Curr Treat Options Neurol. 2019;21:4.
doi: 10.1007/s11940-019-0544-7
pubmed: 30701337
Gomez-Choco M, Iranzo A, Blanco Y, Graus F, Santamaria J, Saiz A. Prevalence of restless legs syndrome and REM sleep behavior disorder in. Mult Scler Mult Scler. 2007;13:805–08.
doi: 10.1177/1352458506074644
pubmed: 17613610
Plazzi G, Montagna P, Remitting REM. sleep behaviour disorder as the initial sign of multiple sclerosis. Sleep Med. 2002;3:437–39.
doi: 10.1016/S1389-9457(02)00042-4
pubmed: 14592179
Enriquez-Marulanda A, Quintana-Peña, Takeuchi Y, Quiñones J. Rapid eye movement sleep behavior disorder as the first manifestation of multiple sclerosis. A case report and literature review. Int J MS Care. 2018;20:180–84.
doi: 10.7224/1537-2073.2017-001
pubmed: 30150902
pmcid: 6107341
Tippmann-Peikert M, Boeve BF, Keegan BM. REM sleep behavior disorder initiated by acute brainstem multiple sclerosis. Neurology. 2006;66:1277–79.
doi: 10.1212/01.wnl.0000208518.72660.ff
pubmed: 16636256
Nishino S, Kanbayashi T, Fujiki N, et al. CSF hypocretin in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology. 2003;61:823–25.
doi: 10.1212/01.WNL.0000081049.14098.50
pubmed: 14504329
pmcid: 14504329
Karkare K, Sinha S, Taly AB, Rao S. Prevalence and profile of sleep disturbances in Guillain-Barre Syndrome: a prospective questionnaire-based study during 10 days of hospitalization. Acta Neurol Scand. 2013;127:116–23.
doi: 10.1111/j.1600-0404.2012.01688.x
pubmed: 22642612
pmcid: 22642612
Gao J, Li Y, Sun Y, Hu W, Liu Y, An D, et al. The study of sleep disorder factors in patients with Guillain-Barré syndrome. Int J Neurosci. 2016;126:893–98.
doi: 10.3109/00207454.2015.1080699
pubmed: 27348620
Bahnasy WS, El-Heneedy YAE, El-Shamy AM, Badr MY, Amer RA, Ibrahim ISE. Sleep and psychiatric abnormalities in Gullian Barré Syndrome. Egypt J Neurol Psychiatr Neurosurg. 2018;54:5.
doi: 10.1186/s41983-018-0007-1
pubmed: 29780225
pmcid: 5954782
Cochen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndrome. Brain. 2005;128:2535–45.
doi: 10.1093/brain/awh585
pubmed: 16000335
Rosenfeld MR, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin. 2018;36:675–85.
doi: 10.1016/j.ncl.2018.04.015
pubmed: 30072076
Höftenberfg R, Rosenfeld M, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27:489–95.
doi: 10.1097/CCO.0000000000000222
Silber MH. Autoimmune sleep disorders. Handb Clin Neurol. 2016;133:317–26.
doi: 10.1016/B978-0-444-63432-0.00018-9
pubmed: 27112685
Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127:1831–44.
doi: 10.1093/brain/awh203
pubmed: 15215214
Blumenthal DT, Salzman KL, Digre KB, Jensen RL, Dunson WA, Dalmau J. Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis. Neurology. 2006;67:146–49.
doi: 10.1212/01.wnl.0000223647.83708.20
pubmed: 16832096
Overeem S, Dalmau J, Bataller L, et al. HCRT-1 CSF levels in anti-Ma2 associated encephalitis. Neurology. 2004;62:138–40.
doi: 10.1212/01.WNL.0000101718.92619.67
pubmed: 14718718
pmcid: 2574537
Hoffmann LA, Jarious S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. 2008;79:767–73.
doi: 10.1136/jnnp.2007.118588
pubmed: 18223018
Landolfi JC, Nadkarni M. Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: case study. Neuro-Oncol. 2003;5:214–16.
doi: 10.1215/S1152851702000467
pubmed: 1920692
pmcid: 1920692
Compta Y, Iranzo A, Santamaria J, Casamitjana R, Graus F. REM sleep behavior disorder and narcolpetic features in anti-Ma2 encephalitis. Sleep. 2007;30:767–69.
doi: 10.1093/sleep/30.6.767
pubmed: 1978347
pmcid: 1978347
Rojas-Marcos I, Graus F, Sanz G, Robledo A, Diaz-Espejo C. Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: case study. Neuro-Oncol. 2007;9:75–77.
doi: 10.1215/15228517-2006-013
pubmed: 1828100
pmcid: 1828100
Sahashi K, Sakai K, Mano K, Hirose G. Anti-Ma2 related paraneoplastic limbic/brain stem encephalitis associated with breast cancer expressing Ma1, Ma2, and Ma3 mRNAs. J Neurol Neurosurg Psychiatry. 2003;74:1332–35.
doi: 10.1136/jnnp.74.9.1332
pubmed: 1738632
pmcid: 1738632
Bennet JL, Galetta SL, Frohman LP, et al. Neuro-opthalamic manifestations of a paraneoplastic syndrome and testicular carcinoma. Neurology. 1999;52:864–67.
doi: 10.1212/WNL.52.4.864
Waragai M, Chiba A, Uchibori A, Fukushima T, Anno A, Tanaka K. Anti-Ma2 associated paarneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry. 2006;77:111–13.
doi: 10.1136/jnnp.2005.068775
pubmed: 2117426
pmcid: 2117426
Scheid R, Voltz R, Guthke T, Sammler D, von Crammon DY. Neuropsychiatric findings in anti-Ma2-positive paraneoplastic limbic encephalitis. Neurology. 2003;61:1159–60.
doi: 10.1212/01.WNL.0000085873.45099.E2
Sutton I, Winner J, Rowlands D, Dalmau J. Limbic encephalitis and antibodies to Ma2: a paraneoplastic presentation of breast cancer. J Neurol Neurosurg Psychiatry. 2000;69:266–68.
doi: 10.1136/jnnp.69.2.266
pubmed: 1737060
pmcid: 1737060
Barnett M, Prosser J, Sutton I, et al. Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. J Neurol Neurosurg Psychiatry. 2001;70:222–25.
doi: 10.1136/jnnp.70.2.222
pubmed: 1737194
pmcid: 1737194
Adams C, McKeon A, Silber MH, Kumar R. Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma. Arch Neurol. 2011;68:521–24.
doi: 10.1001/archneurol.2011.56
Dauvilliers Y, Bauer J, Rigau V. Hypothalamic immunopathologyin anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol. 2013;70:1305–10.
pubmed: 23939463
pmcid: 23939463
Kritikou I, Vgontzas AN, Rapp MA, Bixler EO. Anti-Ma1- and Anti-Ma2-associated encephalitis manifesting with rapid eye movement sleep disorder and narcolepsy with cataplexy: a case report. Biol Psychiatry. 2018;83:e39–40.
doi: 10.1016/j.biopsych.2016.12.014
pubmed: 28117047
pmcid: 28117047
Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133:2734–274.
doi: 10.1093/brain/awq213
pubmed: 20663977
pmcid: 20663977
Iranzo A, Graus F, Clover L, et al. Rapid eye movement sleep behavior disorder and potassium channel antibody–associated limbic encephalitis. Ann Neurol. 2006;59:178–82.
doi: 10.1002/ana.20693
pubmed: 16278841
pmcid: 16278841
Cornellius JR, Pittock SJ, McKeom A, et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68:733–38.
doi: 10.1001/archneurol.2011.106
Tezer I, Erdener E, Sel CC, Mendikanova L, Sagy S, Topcuoglu M. Daytime polysomnography recording in LIG1-related limbic encephalitis. Arch Neurol. 2012;69:145–46.
doi: 10.1001/archneur.69.1.145
pubmed: 22232362
pmcid: 22232362
Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94–114.
doi: 10.1111/nyas.12553
pubmed: 25315420
pmcid: 25315420
Lugaresi E, Provini F. Agrypnia excitata: clinical features and pathophysiological implications. Sleep Med Rev. 2001;5:313–22.
doi: 10.1053/smrv.2001.0166
pubmed: 12530995
pmcid: 12530995
Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, et al. Morvan’s Syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain. 2001;124:2417–26.
doi: 10.1093/brain/124.12.2417
pubmed: 11701596
pmcid: 11701596
Guaraldi P, Calandra-Buonaura G, Terlizzi R, et al. Oneiric stupor: the peculiar behaviour of agrypnia excitata. Sleep Med. 2011;12:S64–67.
doi: 10.1016/j.sleep.2011.10.014
pubmed: 22136903
pmcid: 22136903
Provini P, Marconi M, Amadori M, et al. Morvan chorea and agrypnia excitata: when video-polysomnographic recording guides the diagnosis. Sleep Med. 2011;12:1041–43.
doi: 10.1016/j.sleep.2011.05.005
pubmed: 22033118
Antelmi E, Ferri R, Iranzo A, et al. From state dissociation to status dissociatus. Sleep Med Rev. 2016;28:1–13.
doi: 10.1016/j.smrv.2015.07.003
Vale T, Bizari Fernanes do Prado L, Fernnades Do Prado G, Grazian Povoas Barsittini O, Pedroso JL. Rapid eye movement sleep behavior disorder in paraneoplastic cerebellar degeneration: improvement with immunotherapy. Sleep. 2016;39:117–20.
doi: 10.5665/sleep.5330
pubmed: 26414894
pmcid: 4678340
Iranzo A, Santamaria J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology. 2005;65:247–52.
doi: 10.1212/01.wnl.0000168864.97813.e0
pubmed: 16043794
Iranzo A, Muñoz E, Santamaría J, Vilaseca I, Milà M, Tolosa E. REM sleep behavior disorder and vocal cord paralysis in Machado-Joseph disease. Mov Disord. 2003;18:1179–83.
doi: 10.1002/mds.10509
pubmed: 14534924
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfield MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
doi: 10.1016/S1474-4422(10)70253-2
pubmed: 21163445
pmcid: 3158385
Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–98.
doi: 10.1016/S1474-4422(08)70224-2
pubmed: 18851928
pmcid: 2607118
Forrest D, Yuzaki M, Soares HD, et al. Targeted disruption of the NMDA receptor 1 gene abolishes NMDA response and results in neuronal death. Neuron. 1994;13:325–38.
doi: 10.1016/0896-6273(94)90350-6
pubmed: 8060614
Stamelou M, Plazzi G, Lugaresi E, Edwards MJ, Bathia KP. The distinct movement disorder in anti-NMDA receptor encephalitis may be related to status dissociates: a hypothesis. Mov Disord. 2012;27:1360–63.
doi: 10.1002/mds.25072
pubmed: 22700398
Coban A, Kücükali CI, Yalcinkaya N, et al. Evaluation of incidence and clinical features of antibody-associated autoimmune encephalitis mimicking dementia. Behav Neurol. 2014;2014:935379.
doi: 10.1155/2014/935379
pubmed: 24825964
pmcid: 4006617